Tango Therapeutics, Inc. Increase (Decrease) in Accounts Payable
Tango Therapeutics, Inc. (TNGX) reported Increase (Decrease) in Accounts Payable of $68.32 thousand for the 3-month period ending 2021-03-31, per its 10-Q filed 2021-05-14.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2021-08-09
- Tango Therapeutics, Inc. increase (decrease) in accounts payable for the quarter ending 2021-03-31 was $68.32K.
| Period end | Increase (Decrease) in Accounts Payable 1 month | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 4 month |
|---|---|---|---|
| 2021-03-31 | $68.32K 10-Q · filed 2021-05-14 | ||
| 2020-09-30 | $5.17K 10-Q · filed 2020-11-13 | ||
| 2020-06-30 | $440.00 10-Q · filed 2021-08-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |